141 related articles for article (PubMed ID: 32778976)
1. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 Lung Cancer Cells.
Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
[TBL] [Abstract][Full Text] [Related]
2. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
3. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer.
Gupta B; Poudel BK; Regmi S; Pathak S; Ruttala HB; Gautam M; An GJ; Jeong JH; Choi HG; Yong CS; Kim JO
Pharm Res; 2018 Mar; 35(5):96. PubMed ID: 29536182
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the Uptake Efficiency and Cytotoxicity of Tetrandrine-Loaded Poly(N-vinylpyrrolidone)-Block-Poly(ε-caprolactone) (PVP-b-PCL) Nanoparticles in the A549 Lung Adenocarcinoma Cell Line.
Xu H; Li X; Kong H; Zeng X; Jin Y; Qi Y; Wang H; Xie W
J Biomed Nanotechnol; 2016 Aug; 12(8):1699-707. PubMed ID: 29342348
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
7. An efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasion.
Xu H; Hou Z; Zhang H; Kong H; Li X; Wang H; Xie W
Int J Nanomedicine; 2014; 9():231-42. PubMed ID: 24403829
[TBL] [Abstract][Full Text] [Related]
8. Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method.
Naseri N; Zakeri-Milani P; Hamishehkar H; Pilehvar-Soltanahmadi Y; Valizadeh H
Drug Res (Stuttg); 2017 Jun; 67(6):343-348. PubMed ID: 28288490
[TBL] [Abstract][Full Text] [Related]
9. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer.
Bakhtiary Z; Barar J; Aghanejad A; Saei AA; Nemati E; Ezzati Nazhad Dolatabadi J; Omidi Y
Drug Dev Ind Pharm; 2017 Aug; 43(8):1244-1253. PubMed ID: 28323493
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
12. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy.
Lelj-Garolla B; Kumano M; Beraldi E; Nappi L; Rocchi P; Ionescu DN; Fazli L; Zoubeidi A; Gleave ME
Mol Cancer Ther; 2015 May; 14(5):1107-16. PubMed ID: 25740245
[TBL] [Abstract][Full Text] [Related]
13. Iron Oxide Nanoparticles Synergize with Erlotinib to Suppress Refractory Non-Small Cell Lung Cancer Cell Proliferation Through the Inhibition of ErbB/PI3K/AKT and PTEN Activation.
Zhang M; Sai B; Cao P; Li Z; Zhang L; Shuai C; Wang X; Wang J; Li G; Xiang J; Tang J
J Biomed Nanotechnol; 2017 Apr; 13(4):458-68. PubMed ID: 29388752
[TBL] [Abstract][Full Text] [Related]
14. Encapsulation in lipid-core nanocapsules overcomes lung cancer cell resistance to tretinoin.
Schultze E; Ourique A; Yurgel VC; Begnini KR; Thurow H; de Leon PM; Campos VF; Dellagostin OA; Guterres SR; Pohlmann AR; Seixas FK; Beck RC; Collares T
Eur J Pharm Biopharm; 2014 May; 87(1):55-63. PubMed ID: 24525073
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential.
Pandey P; Dua K; Dureja H
Int J Biol Macromol; 2019 Oct; 139():1304-1316. PubMed ID: 31404602
[TBL] [Abstract][Full Text] [Related]
16. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system.
Pandey P; Chellappan DK; Tambuwala MM; Bakshi HA; Dua K; Dureja H
Int J Biol Macromol; 2019 Dec; 141():596-610. PubMed ID: 31494160
[TBL] [Abstract][Full Text] [Related]
17. A facile approach for fabricating CD44-targeted delivery of hyaluronic acid-functionalized PCL nanoparticles in urethane-induced lung cancer: Bcl-2, MMP-9, caspase-9, and BAX as potential markers.
Parashar P; Tripathi CB; Arya M; Kanoujia J; Singh M; Yadav A; Saraf SA
Drug Deliv Transl Res; 2019 Feb; 9(1):37-52. PubMed ID: 30178279
[TBL] [Abstract][Full Text] [Related]
18. HA/HSA co-modified erlotinib-albumin nanoparticles for lung cancer treatment.
Shen Y; Li W
Drug Des Devel Ther; 2018; 12():2285-2292. PubMed ID: 30087553
[TBL] [Abstract][Full Text] [Related]
19. Beclomethasone Dipropionate-Loaded Polymeric Nanocapsules: Development, In Vitro Cytotoxicity, and In Vivo Evaluation of Acute Lung Injury.
Chassot JM; Ribas D; Silveira EF; Grünspan LD; Pires CC; Farago PV; Braganhol E; Tasso L; Cruz L
J Nanosci Nanotechnol; 2015 Jan; 15(1):855-64. PubMed ID: 26328450
[TBL] [Abstract][Full Text] [Related]
20. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation.
Zhou X; Tao H; Shi KH
Drug Des Devel Ther; 2018; 12():1-8. PubMed ID: 29296076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
